OligodendrogliomaSymptoms, Doctors, Treatments, Advances & More
Oligodendroglioma Overview
Learn About Oligodendroglioma
View Main Condition: Brain Tumor
Dana-Farber Cancer Institute, Center For Neuro-Oncology
Patrick Wen is a Neurologist practicing medicine in Boston, Massachusetts. Dr. Wen is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Wen is board certified in Neurology and Neuro-Oncology.
Cleveland Clinic Main Campus
David Peereboom is an Oncologist and a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. Dr. Peereboom is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioblastoma, Glioma, Astrocytoma, and Bone Marrow Aspiration. Dr. Peereboom is board certified in United Council For Neurological Subspecialties, 2008.
Northwell Health Ambulatory Surgery At The Center For Advanced Medicine
"Michael Schulder, MD, is the vice chair of neurosurgery at North Shore University Hospital and Long Island Jewish Medical Center. He is also the director of the Brain Tumor Center at the Institute for Neurology and Neurosurgery-which treats more than 600 patients annually-and co-director of the Center for Stereotactic Radiosurgery, where his team offers the latest treatment technologies. His research focuses on improving methods of image guidance for brain tumor surgery, and on new techniques for radiosurgery.""I've always been fascinated by the workings of the brain and how it gives rise to our thoughts, memories and personalities in ways that aren't fully understood,"" Dr. Schulder says. He attended medical school at Columbia University College of Physicians and Surgeons, and completed his residency in neurological surgery at the Albert Einstein College of Medicine. Dr. Schulder also trained in stereotactic neuro-oncology at the University of Florida and the Brigham and Women's Hospital.Dr. Schulder works with neuro-oncologists, radiation oncologists and other neurosurgeons to create evidence-based treatment plans. ""We offer close multidisciplinary collaboration to help avoid delay in seeing patients,"" he says. The team strives to offer minimally invasive treatments as often as possible.With a keen interest in neurosurgical image guidance-the use of real-time images of the brain to make procedures safer and more precise-Dr. Schulder is studying the next generation of intraoperative MRI. He runs a brain tumor clinical trials program, giving his patients ready access to innovative approaches to care. While performing complex neurosurgery is one of the most satisfying parts of Dr. Schulder's job, ""empathizing with patients and their families throughout treatment is equally fulfilling,"" he says.In addition to treating brain tumors, Dr. Schulder performs functional neurosurgery to manage pain conditions like trigeminal neuralgia, and movement disorders including essential tremor and Parkinson's disease. He is the program director of neurosurgical residency training at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Schulder is active in organized neurosurgery, where among other offices he is past president of the World Society for Stereotactic and Functional Neurosurgery, director-at-large of the American Association of Neurological Surgeons, and historian of the American Academy Neurological Surgery.". Dr. Schulder is rated as an Elite provider by MediFind in the treatment of Oligodendroglioma. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Oligodendroglioma, Gamma Knife Radiosurgery, and Awake Craniotomy. Dr. Schulder is board certified in American Board Of Neurological Surgery.
Summary: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Funding Source- FDA OOPD
Summary: This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or G...

Keep Punching supports patients, healthcare providers, and researchers in their fight to prevent and eradicate brain cancer and minimize treatment-related side effects that may adversely impact function and comfort.


